» Articles » PMID: 35399520

The Role of Impaired Mitochondrial Dynamics in MFN2-Mediated Pathology

Overview
Specialty Cell Biology
Date 2022 Apr 11
PMID 35399520
Authors
Affiliations
Soon will be listed here.
Abstract

The Mitofusin 2 protein (MFN2), encoded by the gene, was first described for its role in mediating mitochondrial fusion. However, MFN2 is now recognized to play additional roles in mitochondrial autophagy (mitophagy), mitochondrial motility, lipid transfer, and as a tether to other organelles including the endoplasmic reticulum (ER) and lipid droplets. The tethering role of MFN2 is an important mediator of mitochondrial-ER contact sites (MERCs), which themselves have many important functions that regulate mitochondria, including calcium homeostasis and lipid metabolism. Exemplifying the importance of MFN2, pathogenic variants in are established to cause the peripheral neuropathy Charcot-Marie-Tooth Disease Subtype 2A (CMT2A). However, the mechanistic basis for disease is not clear. Moreover, additional pathogenic phenotypes such as lipomatosis, distal myopathy, optic atrophy, and hearing loss, can also sometimes be present in patients with CMT2A. Given these variable patient phenotypes, and the many cellular roles played by MFN2, the mechanistic underpinnings of the cellular impairments by which MFN2 dysfunction leads to disease are likely to be complex. Here, we will review what is known about the various functions of MFN2 that are impaired by pathogenic variants causing CMT2A, with a specific emphasis on the ties between MFN2 variants and MERCs.

Citing Articles

Indole-3-propionic acid promotes hepatic stellate cells inactivation.

Ilha M, Sehgal R, Matilainen J, Rilla K, Kaminska D, Gandhi S J Transl Med. 2025; 23(1):253.

PMID: 40025530 PMC: 11871697. DOI: 10.1186/s12967-025-06266-z.


Mitochondrial Dysfunction in Neurodegenerative Diseases.

Yang H Cells. 2025; 14(4).

PMID: 39996748 PMC: 11853439. DOI: 10.3390/cells14040276.


Targeting membrane contact sites to mediate lipid dynamics: innovative cancer therapies.

Wang J, Wang M, Zeng X, Li Y, Lei L, Chen C Cell Commun Signal. 2025; 23(1):89.

PMID: 39955542 PMC: 11830217. DOI: 10.1186/s12964-025-02089-z.


Pharmacologic activation of integrated stress response kinases inhibits pathologic mitochondrial fragmentation.

Baron K, Oviedo S, Krasny S, Zaman M, Aldakhlallah R, Bora P Elife. 2025; 13.

PMID: 39937095 PMC: 11820110. DOI: 10.7554/eLife.100541.


Mitofusin 2 displays fusion-independent roles in proteostasis surveillance.

Joaquim M, Altin S, Bulimaga M, Simoes T, Nolte H, Bader V Nat Commun. 2025; 16(1):1501.

PMID: 39929801 PMC: 11811173. DOI: 10.1038/s41467-025-56673-5.


References
1.
Muglia M, Vazza G, Patitucci A, Milani M, Pareyson D, Taroni F . A novel founder mutation in the MFN2 gene associated with variable Charcot-Marie-Tooth type 2 phenotype in two families from Southern Italy. J Neurol Neurosurg Psychiatry. 2007; 78(11):1286-7. PMC: 2117589. DOI: 10.1136/jnnp.2007.115774. View

2.
Martins de Brito O, Scorrano L . Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature. 2008; 456(7222):605-10. DOI: 10.1038/nature07534. View

3.
Engelfried K, Vorgerd M, Hagedorn M, Haas G, Gilles J, Epplen J . Charcot-Marie-Tooth neuropathy type 2A: novel mutations in the mitofusin 2 gene (MFN2). BMC Med Genet. 2006; 7:53. PMC: 1524942. DOI: 10.1186/1471-2350-7-53. View

4.
Theurey P, Tubbs E, Vial G, Jacquemetton J, Bendridi N, Chauvin M . Mitochondria-associated endoplasmic reticulum membranes allow adaptation of mitochondrial metabolism to glucose availability in the liver. J Mol Cell Biol. 2016; 8(2):129-43. DOI: 10.1093/jmcb/mjw004. View

5.
Hertlein V, Flores-Romero H, Das K, Fischer S, Heunemann M, Calleja-Felipe M . MERLIN: a novel BRET-based proximity biosensor for studying mitochondria-ER contact sites. Life Sci Alliance. 2019; 3(1). PMC: 6910062. DOI: 10.26508/lsa.201900600. View